Harnessing Artificial Intelligence for the Management of Patients With GI Cancers.

Lipika Goyal¹, Caroline Chung², Yuichi Mori³, William A Hall⁴, Kenneth L Kehl⁵, Mary Feng⁶

¹Stanford Cancer Center, Stanford School of Medicine, Stanford, CA.

²Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

³Clinical Effectiveness Research Group, University of Oslo and Oslo University Hospital, Oslo, Norway.

⁴Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.

⁵Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.

⁶University of California San Francisco, San Francisco, CA.

PubMed DOI

Abstract

Artificial intelligence (AI) has the potential of reshaping GI oncology by enabling more nuanced interpretation of complex clinical, imaging, and molecular data, while supporting more timely and patient-centered decisions. This article synthesizes perspectives across the GI cancer continuum, beginning with a framework for context-aware AI that emphasizes metadata, multimodal integration, and lifec…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.